Shanghai Junshi Biosciences (HKG:1877, SHA:688180) booked an attributable profit of 25.5 million yuan in the first half of 2026, returning from a loss of 413.4 million yuan a year prior, a Wednesday Hong Kong bourse filing said.
Earnings per share stood at 0.02 yuan, compared with a loss per share of 0.42 yuan in the year-ago period.
Revenue for the interim period increased 45% to 1.70 billion yuan from 1.17 million yuan in the corresponding period of the last year.